Experience and Early Outcome of Treating Retrograde Type A Dissection with Primary Entry Tear in the Descending Thoracic Aorta.
Zhang Wan,Dong Zhi-hui,Fu Wei-guo,Guo Da-qiao,Xu Xin,Wang Yu-qi
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20132105
IF: 6.133
2013-01-01
Chinese Medical Journal
Abstract:Once the ascending aorta gets involved and however farther the dissection extends, it is named type A dissection (TAD), in which the entry tear usually locates in the ascending aorta. But there exists a small subset with primary entry tear in the descending aorta and the dissection process extends back into the ascending aorta, which here we name primary retrograde type A dissection (PRTAD). Operative procedures are far more difficult and extensive for PRTAD and usually result in poor prognosis in the aspects of surgical mortality and survival rate during follow-up.1–3 Kato et al4 and Chang et al5 showed successful method of endovascular repair for PRTAD and recommended it as an alternative to the operative treatment. During March 2008 to August 2010, five continuous patients with PRTAD were admitted into our institution. We here introduce our preliminary experience with medical therapy and thoracic endovascular aortic repair (TEVAR) for treating PRTAD. METHODS Patient selection and demographics Inclusion criteria: (1) TAD with primary entry tear in the descending aorta; (2) no signs of cardiac tamponade or severe aortic regurgitation; (3) no signs of ischemia of the coronary artery or arch branches. Between March 2008 and August 2010, totally 359 patients of type B dissection were admitted into our institution all diagnosed by computed tomographic angiography (CTA), mostly from various hospitals throughout China. We rearranged CTA for each patient and found that seven patients were eventually TAD: one patient with the entry tear in the ascending aorta complicating by lesions of three main coronary arteries, and the remaining six patients were actually PRTAD: one patient had uncontrollable chest pain and impending aortic rupture, and was referred to Department of Cardiac Surgery for emergent surgical aortic repair. Finally, the remaining five patients all got stabilized with medical therapy initially. Detailed demographics such as patient age, gender, comorbidity and the phase of dissection were collected. Treatment strategy and stent graft placement Once vitals were stabilized, further treatment was applied, either simply medically or additionally by TEVAR. Medical therapy was composed of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or calcium antagonists administrated alone or in combination. Close observation was managed to maintain the systolic blood pressure of less than 140 mmHg. The endovascular procedure has been described in detail elsewhere.6 Important aspects potentially associated with PRTAD are highlighted as follows. Oversizing rate was between 10%-15% according to aortic diameter of proximal anchoring site (including both the true lumen and the false lumen). If the proximal landing zone, the distance from the origin of left subclavian artery (LSA) to primary entry site, was less than 15 mm, coverage of LSA was intentionally applied in order to create an extra anchoring area. Stent graft system There were three types of stent graft systems used in the study, including Hercules (Microport, China), Valiant (Medtronic, USA), and Zenith TX2 (Cook, USA), with the graft ranging from 150 to 160 mm in length and from 38 to 40 mm in diameter. Follow-up protocol and data collection All the patients were followed up by CTA at 1, 3, and 6 months and yearly thereafter after treatment. The diameter of the aorta is reported as mean±standard deviation. All the statistics of patient information and aortic diameter measurements from every CTA were collected by the author. RESULTS Patient demographics and characteristics Among the five PRTAD patients, three were male and two female, with mean age of (60±16) years (range, 36-85 years); three were in the acute phase, one in the subacute phase, and one in the chronic phase. The acute phase was defined as within 2 weeks after symptom onset, and the subacute phase was the following 2-month period; with anything thereafter called the chronic phase. Detailed patient demographics and clinical characteristics were listed in Table 1.Table 1: Patient demographics and clinical charateristicsTreatment strategy Once blood pressure got stabilized and fully considered all the patients' conditions, we continued medical therapy for patient 4 because of advanced age and malignant tumor resulting in short life expectancy and patient 5 for financial reasons. Patient 1, patient 2, and patient 3 underwent TEVAR at last (Table 1). Immediate outcomes of TEVAR Technical success was achieved in all 3 TEVAR cases. In order to acquire adequate proximal landing zone, LSA was intentionally covered in patient 2 and partially covered in patient 1, in whom proximal type I endoleak was detected on the completion angiogram and significantly resolved after a quick gentle ballooning. No procedure-related complications occurred. Follow-up outcomes All patients (patients 1-5) were followed up with an average period of (4.6±2.7) months (range, 1-11 months), and free from procedure-related complications. CTA images revealed neither edema around ascending aorta and aortic arch, nor new entry at either end of the stent graft. The false lumen was completely thrombosed in patient 1, patient 3, and patient 5, and partially thrombosed in patient 2 and patient 4. Table 2 showed the aorta diameter measurement before and after treatment in the segment of ascending aorta, aortic arch, aorta of the anchoring site, and true lumen of the descending aorta. Mean diameter before treatment was (38.4±7.4), (30.0±7.1), (33.3±2.3), and (34.0±8.1) mm, respectively. According to the latest follow-up CTA, there was slight enlargement of the ascending aorta, aortic arch, and aorta of the anchoring site which reached (40.4±4.3), (33.4±3.8), and (38.0±1.7) mm, respectively; however, the true lumen of descending aorta remained relatively stable, (33.9±6.5) mm (Figure 1). The average diameter of ascending aorta, aortic arch, and the anchoring site of the TEVAR patients increased by 3.7, 5.3, and 4.7 mm respectively (Table 2). Meanwhile, mean diameter of the descending aorta decreased by 4.0 mm, which may be caused by thrombosis of the false lumen. The aorta segment of diaphragm expanded slightly by 1.3 mm. On the contrary, aorta remodeling of patients with medical therapy seemed different. The mean diameter of ascending aorta and aortic arch showed no obvious change, while that of descending aorta and segment of diaphragm expanded slightly by 3.5 and 5.5 mm, respectively.Table 2: Diameter measurement of CTA images of TEVAR and medical therapy (mm)Figure 1.: CTA images of patient 3 with TEVAR, the preoperative CTA showing the primary tear located immediately distal to LSA with thrombosed false lumen at the aortic arch and an intact ascending aorta (A, B), follow-up CTA at 3 months demostrating the complete false lumen thrombosis, the satisfactory aortic remodeling, and freedom from new-onset dissection or aneurysmal dilation (C, D).DISCUSSION In our center, PRTAD approximately stood for 1.7 % (6/358) of all the type B dissection. As far as we know, there existed controversies on its optimal treatment, and reports in this regard were rare. In this study, we discussed our acceptable preliminary experience of treating PRTAD with TEVAR and medical therapy as well. The rationale for TEVAR for PRTAD lays great emphasis on complete entry closure in the descending aorta and subsequent complete thrombosis of false lumen, which is almost similar to that for type B dissection. Kato et al4 and Chang et al5 have already showed successful experience in treating PRTAD with stent-graft placement and recommended it as an alternative to the surgical treatment. In our study, CTA images of all patients showed a predominant distal dissection in the discending aorta, with almost intact, thrombosed, and relatively small ascending aorta and aortic arch. Meanwhile, all the patients were stabilized with initial medical therapy. Given potential risks associated with the surgical aortic replacement, TEVAR was considered a reasonable alternative. TEVAR was ultimately applied to three patients. On the other hand, there were some TEVAR-specific concerns in patients with PRTAD: if such fragile and dissected proximal landing zone sustain the radial force of the stent-graft, and if the proximal fixation device of the endograft, such as bards of Zenith TX2 and the bare spring of Valiant, yields newly developed dissection or even aortic rupture. Ultimately, all three cases recovered uneventfully from TEVAR and remained free from dissection- or TEVAR-related complications during the follow-up. Compared to the usual type B dissection, PRTAD was characteristic of an unhealthy proximal landing zone, which resultantly posed the great concern of whether TEVAR would increase the risk of stent-graft-induced new entry. According to Dong et al,7 the incidence of stent-graft-induced new entry reached 3.4%, which were 22 out of 650 patients after TEVAR for type B dissection. And, the underlying causes for this complication included spring-back force from the passively curved stent graft when placed across the aortic arch potential injury of its proximal bare stent or barbs, and its radial force as well. The former two causes highly associated with the material property and design of the stent graft, which are impractical to be changed overnight. As for the radial force, however, it could be put under control via an appropriate stent graft oversizing by doctors during the pre-procedural evaluation. Therefore, in order to minimize the radial-force-induced injury, we used the diameter of the whole aorta including both the true and false lumina as the baseline for oversizing of the stent graft. Ultimately, there was no development of stent-graft-induced new entry in all TEVAR cases, suggesting the safety and feasibility of TEVAR for PRTAD. To date, medical therapy remains the first choice for uncomplicated type B dissection. Medical therapy should also be recommended for PRTAD due to its primary entry site in the descending aorta, in the setting of an intact ascending aorta with a thrombosed false lumen and no aneurysmal dilation. For the two medically treated cases in the current study, partial and complete false lumen thrombosis of the thoracic aorta were evidenced on follow-up CTA at 1 and 5 months, respectively, consistent with the fact that the simple medical treatment could also yield satisfactory outcomes. Nevertheless, CTA identified enlargement of the descending thoracic aorta in them during the follow-up, indicating relatively poorer aortic remodeling after the mere medical management. As was known, continuous aneurysmal dilation of aorta was responsible for the main stream of dissection related death due to the resultant lethal aortic rupture. Furthermore, though more than 90% of patients with uncomplicated type B dissection could luckily survive with medical therapy alone, it was unfortunately not so in terms of the three-year survival rate, which decreased to 78%, and the 5-year survival rate after firstly diagnosed was dramatically low ranging from 48% to 82%. Therefore, medical therapy alone could only be recommended in highly selected patients with serious comorbidities and short life expectancy.